| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | 1 |
| Sell | — | — | 1 | 7 | 2 | 4 | — | 1 | 1 | 1 | 1 | 1 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 340.45 | 834.19 | 637.56 | 635.21 |
| Receivables | — | 4.95 | — | — |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 346.79 | 863.41 | 675.70 | 659.21 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 16.92 | 4.74 | 8.97 | 5.42 |
| ST’ Debt | — | — | — | — |
| Other | 12.57 | 82.31 | 57.27 | 54.45 |
| 49.90 | 106.92 | 85.79 | 72.97 |
| 10y | 5y | 3y | |
| Sales | — | — | ‡‡‡‡‡ |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 3.04 | 3.70 | — | — |
—
|
| ’25 | 2.98 | 19.15 | 0.35 | 0.03 |
22.50
|
| ’24 | 1.40 | 2.28 | 29.11 | 12.77 |
45.56
|
| ’23 | 8.63 | 10.33 | 2.94 | 0.80 |
14.09
|
| ’22 | — | — | — | — |
102.69
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (30.60) | (39.21) | — | — |
—
|
| ’25 | (36.47) | (37.67) | (32.77) | (40.87) |
(147.78)
|
| ’24 | (54.60) | (53.98) | (12.50) | (37.48) |
(158.56)
|
| ’23 | (31.86) | (36.68) | (39.60) | (33.07) |
(141.22)
|
| ’22 | (0.39) | (0.17) | (0.24) | 11.47 |
10.67
|
| ’22 | — | — | — | — |
8.38
|
| ’21 | (0.20) | (0.37) | (0.15) | 0.59 |
(0.14)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (30.64) | (39.29) | — | — |
—
|
| ’25 | (36.48) | (37.76) | (32.81) | (40.97) |
(148.03)
|
| ’24 | (54.99) | (54.19) | (12.58) | (37.48) |
(159.24)
|
| ’23 | (31.87) | (36.68) | (39.62) | (33.08) |
(141.24)
|
| ’22 | (0.39) | (0.17) | (0.24) | 11.25 |
10.44
|
| ’22 | — | — | — | — |
8.38
|
| ’21 | (0.20) | (0.37) | (0.15) | 0.57 |
(0.16)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.40) | (0.52) | — | — |
—
|
| ’25 | (0.34) | (0.15) | (0.61) | (0.63) |
(1.72)
|
| ’24 | (1.06) | (0.41) | (0.18) | (0.95) |
(2.56)
|
| ’23 | — | (0.99) | — | — |
(2.15)
|
| ’22 | — | — | — | — |
(1.01)
|
| ’22 | 0.16 | (0.07) | 0.10 | — |
(1.01)
|
| ’21 | — | — | 0.00 | 0.00 |
(1.40)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | ‡‡‡‡ | 7.52 | 5.63 | 11.18 | 14.06 | — | — | — |
Low Price
|
| — | — | — | — | — | ‡‡‡‡‡ | 32.88 | 18.70 | 27.29 | 42.00 | — | — | — |
High Price
|
| — | — | — | — | ‡‡‡ | ‡‡‡ | 17 | 29 | 68 | 100 | — | — | — |
Employees
|
| — | — | — | — | ‡‡‡ | ‡‡‡ | 0.00 | 0.49 | 0.67 | 0.23 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | — | 102.47 | 14.09 | 45.56 | 22.50 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| — | — | — | — | — | ‡‡‡ | 99.93% | 100.00% | 100.00% | 100.00% | — | — | — |
Gross Margin
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (82.03) | (176.91) | (241.60) | (203.82) | — | — | — |
EBT
|
| — | — | — | — | ‡‡‡ | ‡‡‡ | (80.05%) | (1,255.57%) | (530.25%) | (905.74%) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| — | ‡‡‡ | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (82.03) | (176.94) | (241.60) | (203.82) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.08 | 0.05 | 0.11 | 0.22 | — | — | — |
Depreciation
|
| — | — | — | — | ‡‡‡ | ‡‡‡ | 1.26 | 0.17 | 0.48 | 0.19 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| — | — | — | — | ‡‡‡ | ‡‡‡‡ | (1.01) | (2.15) | (2.56) | (1.72) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.10 | (1.72) | (1.68) | (1.25) | — | — | — |
Cash Flow/Sh
|
| — | — | — | — | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | (0.01) | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.10 | (1.72) | (1.69) | (1.25) | — | — | — |
Free CF/Sh
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 6.34 | 3.51 | 8.03 | 5.77 | — | — | — |
Book Value/Sh
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 81.56 | 82.16 | 94.36 | 118.42 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | — | — | — | — | 40.83 | 0.00 | 0.00 | 0.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
PE Ratio
|
| — | — | — | — | — | — | 0.00 | 43.24 | 53.22 | 184.61 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | — | — | — | — | 0.00 | 3.40 | 3.20 | 6.08 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | — | — | — | — | 0.00 | 28.25 | 34.92 | 156.28 | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| — | — | — | — | — | — | (235.45) | (4.54) | (9.99) | (23.76) | — | — | — |
EV/FCF
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 8.38 | (141.22) | (158.56) | (147.78) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.01) | (0.02) | (0.67) | (0.25) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Capex
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 8.38 | (141.24) | (159.24) | (148.03) | ‡‡‡‡‡ | — | — |
FCF
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 440.42 | 296.89 | 756.50 | 589.91 | — | — | — |
Working Cap'
|
| — | — | — | — | — | ‡‡‡‡‡ | 0.13 | — | — | — | — | — | — |
Total Debt
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (467.89) | (340.45) | (834.19) | (637.56) | — | — | — |
Net Debt
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 517.11 | 288.39 | 757.50 | 683.43 | — | — | — |
Sh' Equity
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (23.21%) | (42.86%) | (39.88%) | (24.95%) | — | — | — |
ROA
|
| — | — | — | — | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | (307.51%) | — | — | — |
ROIC
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (32.12%) | (49.25%) | (46.20%) | (28.29%) | — | — | — |
ROE
|
NewAmsterdam Pharma (NAMS), a clinical-stage biopharma spun out from Amgen and public via SPAC in 2021, is riding high on its oral CETP inhibitor obicetrapib, which has delivered blockbuster Phase 3 results like TANDEM’s superior LDL reductions with statins and BROADWAY monotherapy wins. These catalysts have fueled wild stock swings—from 2022 peaks near $33 on trial hype to 2023 lows around $5.60 amid revenue drops—highlighting biotech’s binary thrill, with 2024 highs rebounding to $27 on fresh data.
Financials reveal a classic pre-profit scaler: Revenue volatile at $45.6 million in 2024 (up 223% YoY) from partnerships, near-100% gross margins, but R&D-fueled losses ballooning to -$242 million. A robust balance sheet shines with $756 million working capital and net cash of $834 million, supporting forecasts of revenue exploding to $162 million by 2027 (328% growth) en route to breakeven, though dilution and negative cash flows persist.
Analysts eye 41% average upside (highs at 73%), pricing in obicetrapib’s FDA potential by 2026-27 against injectables, tempered by insider sells (routine exec exercises) offset by director buys signaling confidence. With PERIGEE trial readouts and Q4 2025 earnings looming, NAMS offers high-reward volatility for patient risk-takers—will it clear the path to profitability?
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.